Bruce E Sands Selected Research

Ulcerative Colitis

12/2022	Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
8/2022	Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
5/2022	Personalised Medicine with IL-23 Blockers: Myth or Reality?
2/2022	Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD.
1/2022	Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
1/2022	Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open.
1/2022	Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
1/2022	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program.
1/2022	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
1/2022	Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bruce E Sands Research Topics

Disease

77	Ulcerative Colitis 12/2022 - 09/2004
74	Crohn Disease (Crohn's Disease) 12/2022 - 11/2003
32	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 05/2022 - 07/2006
27	Infections 11/2022 - 09/2004
13	Inflammation (Inflammations) 12/2021 - 11/2005
10	Necrosis 12/2021 - 01/2011
8	Neoplasms (Cancer) 01/2021 - 10/2009
6	Skin Neoplasms (Skin Cancer) 01/2022 - 01/2017
6	Body Weight (Weight, Body) 01/2019 - 02/2004
5	Hemorrhage 12/2022 - 12/2005
5	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 08/2010
5	Lymphoma (Lymphomas) 10/2010 - 08/2006
4	Herpes Zoster 01/2022 - 01/2017
4	Rheumatoid Arthritis 01/2021 - 08/2010
4	Colitis 03/2016 - 12/2008
4	Fistula 09/2007 - 02/2004
3	Disease Progression 12/2022 - 01/2021
3	Ulcer 11/2022 - 04/2012
3	Sepsis (Septicemia) 08/2022 - 08/2006
3	Diarrhea 01/2016 - 05/2003
3	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 10/2015 - 05/2003
3	Progressive Multifocal Leukoencephalopathy 01/2014 - 09/2007
2	Basal Cell Carcinoma (Rodent Ulcer) 08/2022 - 10/2012
2	Psoriatic Arthritis 01/2022 - 01/2021
2	Melanoma (Melanoma, Malignant) 12/2020 - 01/2019
2	Opportunistic Infections (Opportunistic Infection) 01/2019 - 10/2010
2	Pathologic Constriction (Stenosis) 01/2018 - 08/2015
2	Abdominal Pain (Pain, Abdominal) 08/2013 - 12/2003
2	Abscess 09/2007 - 10/2006
1	Proctitis 11/2022
1	Wounds and Injuries (Trauma) 11/2022
1	Malnutrition (Nutritional Deficiencies) 05/2022
1	Atherosclerosis 01/2021
1	Spontaneous Abortion (Miscarriage) 01/2021
1	Hyperlipidemias (Hyperlipidemia) 01/2021
1	Premature Birth (Birth, Premature) 01/2021
1	Heart Arrest (Cardiac Arrest) 12/2020
1	West Nile Fever 10/2020
1	Encephalitis (Encephalitis, Rasmussen) 10/2020
1	Hepatocellular Carcinoma (Hepatoma) 10/2020

Drug/Important Bio-Agent (IBA)

28	vedolizumabIBA 01/2022 - 08/2013
19	Infliximab (Remicade)FDA Link 01/2018 - 02/2004
17	tofacitinibIBA 01/2022 - 01/2017
14	Ustekinumab (CNTO 1275)FDA Link 12/2022 - 10/2012
12	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2022 - 10/2006
11	Tumor Necrosis Factor InhibitorsIBA 01/2022 - 10/2012
10	Biological ProductsIBA 12/2022 - 08/2007
10	Pharmaceutical PreparationsIBA 11/2022 - 07/2004
9	Interleukin-23 (Interleukin 23)IBA 05/2022 - 07/2010
9	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 01/2004
9	SteroidsIBA 01/2022 - 12/2003
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2009
8	Janus Kinase InhibitorsIBA 01/2022 - 01/2017
8	Monoclonal AntibodiesIBA 01/2022 - 02/2004
8	Immunologic Factors (Immunomodulators)IBA 01/2020 - 12/2008
7	Leukocyte L1 Antigen Complex (Calgranulin)IBA 12/2022 - 12/2012
7	IntegrinsIBA 10/2020 - 08/2013
6	C-Reactive ProteinIBA 12/2022 - 10/2015
5	CytokinesIBA 05/2022 - 08/2007
5	Interleukin-12 (IL 12)IBA 01/2020 - 07/2010
4	Adalimumab (Humira)FDA Link 11/2022 - 01/2019
3	LipidsIBA 01/2021 - 01/2017
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2015
3	acceleratory factor from growth hormone (AcG)IBA 07/2018 - 01/2013
3	Natalizumab (Tysabri)FDA Link 01/2017 - 01/2007
2	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 08/2022 - 10/2008
2	InterleukinsIBA 01/2022 - 12/2012
2	InterferonsIBA 12/2021 - 07/2017
2	Immunoglobulin A (IgA)IBA 01/2021 - 05/2015
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 01/2016
2	GED0301IBA 01/2020 - 01/2018
2	Immunosuppressive Agents (Immunosuppressants)IBA 09/2019 - 01/2019
2	Janus KinasesIBA 11/2018 - 01/2018
2	Methotrexate (Mexate)FDA LinkGeneric 10/2018 - 08/2010
2	AlbuminsIBA 08/2017 - 01/2015
2	eldelumabIBA 07/2017 - 04/2016
2	salicylhydroxamic acid (SHAM)IBA 09/2013 - 08/2008
2	LigandsIBA 12/2012 - 03/2008
2	Azathioprine (Imuran)FDA LinkGeneric 01/2012 - 10/2008
2	Sodium Glutamate (Accent)IBA 04/2005 - 10/2004
2	alosetron (Lotronex)FDA Link 03/2004 - 05/2003
1	MicronutrientsIBA 05/2022
1	mirikizumabIBA 01/2022
1	guselkumabIBA 01/2022
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 12/2021
1	secreted phosphoprotein 24IBA 11/2021
1	etrasimodIBA 06/2021
1	CholesterolIBA 01/2021
1	lipoprotein cholesterolIBA 01/2021
1	Blood Proteins (Serum Proteins)IBA 01/2021
1	2-mercaptopurineIBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2020
1	LactoferrinIBA 01/2020
1	OligodeoxyribonucleotidesIBA 01/2020

Therapy/Procedure

61	Therapeutics 12/2022 - 12/2003
6	Colectomy 01/2018 - 08/2007
5	Biological Therapy 02/2022 - 01/2012
4	Blood Component Removal (Apheresis) 09/2013 - 07/2006
2	Appendectomy 11/2008 - 10/2007
1	Wearable Electronic Devices 01/2021